Literature DB >> 3189442

Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors.

S C Rubin1, W J Hoskins, T B Hakes, M Markman, J M Cain, J L Lewis.   

Abstract

To determine the long-term rate of recurrence and define risk factors for recurrence, we have analyzed clinical information on 83 patients followed up for a minimum of 4 years (median, 69 months) after negative second-look laparotomy. Overall, 21 of 83 patients (25.3%) had a recurrence. Median interval to recurrence was 14 months. Stage, grade, and type of chemotherapy were significantly related to risk of recurrence. In patients with stage I disease only one of 27 (3.7%) had a recurrence. Patients with stage I disease were not included in further analysis of risk factors. In stages II, III, and IV, 20 of 56 patients (35.7%) had a recurrence. Recurrence rates by grade (excluding stage I) are as follows: grade 1, three of 21 (14.3%); grade 2, six of 17 (35.5%), and grade 3, 11 of 17 (64.7%). Platinum-treated patients in stages II, III, and IV had a 50% (12/24) recurrence rate compared with 25% in nonplatinum-treated patients (8/32) (p = 0.05). Differences in disease-free survival between platinum- and nonplatinum-treated patients were significant at the p = 0.02 level. When treated with platinum-based regimens, more patients will achieve complete clinical remission and subsequently negative second-look laparotomy. However, the recurrence rate in these patients is considerably higher than that in patients treated for longer durations with nonplatinum regimens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189442     DOI: 10.1016/0002-9378(88)90420-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  Second-look laparotomies in ovarian cancer: a medical oncologist's perspective.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Resection guided by antibodies (REGAJ): a diagnostic procedure during second-look operation in ovarian cancer patients.

Authors:  W Jäger; H Feistel; E M Paterok; G Ronay; A H Tulusan; F Wolf; N Lang
Journal:  Br J Cancer Suppl       Date:  1990-07

Review 5.  Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes.

Authors:  Harveshp Mogal; Konstantinos Chouliaras; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  J Gastrointest Oncol       Date:  2016-02

6.  Ovarian cancer: opportunity for targeted therapy.

Authors:  Tomoko Tagawa; Robert Morgan; Yun Yen; Joanne Mortimer
Journal:  J Oncol       Date:  2011-12-22       Impact factor: 4.375

Review 7.  Targeting signaling pathways in epithelial ovarian cancer.

Authors:  Elisabeth Smolle; Valentin Taucher; Martin Pichler; Edgar Petru; Sigurd Lax; Johannes Haybaeck
Journal:  Int J Mol Sci       Date:  2013-05-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.